Dr. Sehgal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3090Fax+1 617-632-4448
Education & Training
Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 2018 - 2020
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017- Yale-New Haven Medical CenterPost-Doctoral Fellowship, Allergy and Immunology, 2011 - 2014
All India Institute of Medical SciencesClass of 2010, MBBS
Certifications & Licensure
MA State Medical License 2020 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer Start of enrollment: 2016 Jan 01
Roles: Contact, Principal Investigator
- Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Start of enrollment: 2023 May 20
Roles: Principal Investigator, Contact
- Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors Start of enrollment: 2023 Dec 21
Roles: Contact
Publications & Presentations
PubMed
- Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.Soravis Osataphan, Muhammad Awidi, Yu Jen Jan, Krishna Gunturu, Shriram Sundararaman
Lung Cancer. 2024-12-01 - Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on...Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi A Butler, John K Wiencke
NPJ Precision Oncology. 2024-11-18 - 1 citationsDual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.Kartik Sehgal, Theodora Pappa, Kee-Young Shin, Julia Schiantarelli, Mofei Liu
JAMA Oncology. 2024-10-24
Press Mentions
Pembrolizumab Boosts Survival in Anaplastic Thyroid CancerNovember 5th, 2024- Precision Medicine Approach Shows Promise for Anaplastic Thyroid CancerOctober 25th, 2024
- These Risk Factors Could Predict Whether You’ll Get Long COVIDJanuary 26th, 2022
- Join now to see all
Professional Memberships
- Member
Other Languages
- Hindi
External Links
- Harvard Profilehttps://connects.catalyst.harvard.edu/Profiles/display/Person/161752
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
